Kim Jong Man, Kwon Choon Hyuck David, Joh Jae-Won, Sinn Dong Hyun, Choi Gyu-Seong, Paik Seung Woon
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ann Surg Treat Res. 2018 Apr;94(4):183-189. doi: 10.4174/astr.2018.94.4.183. Epub 2018 Mar 26.
Preoperative F-18-fluoro-2-deoxy-glucose positron emission tomography (18F-FDG PET) imaging results appear to predict tumor recurrence and patient survival. The present study compared outcomes between PET-positive and PET-negative groups with HBV-related hepatocellular carcinoma (HCC) who underwent curative hepatectomy and assessed the prognostic value of positive PET-CT for HCC recurrence and death.
This study included patients who underwent liver resection of solitary HCC between 2007 and 2014 based on preoperative radiological images. There were 133 patients in the PET-positive group and 93 in the PET-negative group.
There were no statistically significant differences in baseline, perioperative, or pathologic characteristics between the 2 groups except HBsAg titer, tumor size, and presence of bile duct tumor thrombi. Multivariate analysis showed that tumor size >3.5 cm and HBsAg titer >1,000 cutoff index were predisposing factors of positive PET-CT. Disease-free survival and overall survival rate at 1, 3, and 5 years were 76.3%, 64.4%, 60.3% and 96.8%, 91.1%, 85.1% in the PET-negative group, respectively, compared with 70.7%, 62.2%, 58.9% and 98.5%, 97.0%, 97.0% in the PET-positive group (P = 0.547 and P = 0.046). Multivariate analysis showed that positive PET-CT was closely associated with increased patient survival, but was not related to HCC recurrence.
These results suggest that positive PET findings are not a predisposing factor for recurrence of HBV-related HCC patients, but appear to be associated with improved patient survival. Further prospective studies are needed to confirm the prognostic value of 18F-FDG PET in these patients.
术前F-18-氟-2-脱氧葡萄糖正电子发射断层扫描(18F-FDG PET)成像结果似乎可预测肿瘤复发和患者生存率。本研究比较了接受根治性肝切除术的HBV相关肝细胞癌(HCC)患者中PET阳性组和PET阴性组的预后,并评估了PET-CT阳性对HCC复发和死亡的预后价值。
本研究纳入了2007年至2014年间根据术前影像学图像接受孤立性HCC肝切除术的患者。PET阳性组有133例患者,PET阴性组有93例患者。
除HBsAg滴度、肿瘤大小和胆管肿瘤血栓外,两组在基线、围手术期或病理特征方面无统计学显著差异。多因素分析显示,肿瘤大小>3.5 cm和HBsAg滴度>1000临界指数是PET-CT阳性的易感因素。PET阴性组1年、3年和5年的无病生存率和总生存率分别为76.3%、64.4%、60.3%和96.8%、91.1%、85.1%,而PET阳性组分别为70.7%、62.2%、58.9%和98.5%、97.0%、97.0%(P = 0.547和P = 0.046)。多因素分析显示,PET-CT阳性与患者生存率提高密切相关,但与HCC复发无关。
这些结果表明,PET阳性结果不是HBV相关HCC患者复发的易感因素,但似乎与患者生存率提高有关。需要进一步的前瞻性研究来证实18F-FDG PET在这些患者中的预后价值。